Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) – a study protocol

BACKGROUND: Patients with type 2 diabetes (T2D) are at increased risk for developing cancer. As approximately 8% of the world’s population is living with T2D, even a slight increase in cancer risk could result in an enormous impact on the number of persons developing cancer. In addition, several glu...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrijnders, Dennis, de Bock, Geertruida H., Houweling, Sebastiaan T., van Hateren, Kornelis J. J., Groenier, Klaas H., Johnson, Jeffrey A., Bilo, Henk J. G., Kleefstra, Nanne, Landman, Gijs W. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482962/
https://www.ncbi.nlm.nih.gov/pubmed/28645260
http://dx.doi.org/10.1186/s12885-017-3433-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482962/
https://www.ncbi.nlm.nih.gov/pubmed/28645260
http://dx.doi.org/10.1186/s12885-017-3433-z

Ejemplares similares